Abbott Laboratories

July 2012 Volume 2 Issue 3

PharmaDeals Corp-METRx is designed to provide vital company metrics for financial and investment bank analysts.

Updated monthly, it provides key metrics on the relative strengths and weaknesses of the world's top 12 pharmaceutical companies.

Delivered in concise and accessible formats online, this publication provides an essential look-up for key facts about company rankings that increases work efficiencies and helps decision making.

Source Data

The source of this data is PharmaDeals v4 Agreements, published by PharmaDeals Ltd, as well as published company reports. PharmaDeals makes every endeavour to achieve comprehensive coverage of all publicly available and significant deals, although does not warrant completeness.

Abbott Laboratories | AstraZeneca | Bayer Healthcare Bristol-Myers Squibb | Eli Lilly | GlaxoSmithKline | Johnson & Johnson Merck | Novartis | Pfizer | Roche | Sanofi PharmaDeals Corp-METRx

Company metrics for financial and investment bank analysts

Activity area	Deal Activity			
Criteria	Licensing deal activity is generally focused around bringing valuable new drugs and drug development programmes into the company. The intensity of activity as compared with the peer group indicates how successful the company is at attracting and securing strategic partnerships, and how relatively weak the internal pipeline is in addressing future revenue and profit challenges.			
Ranking	Overall Deal Activity		Peer Group Status	
Overall deal activity rank	Deals vs Peers	12th	Very Low	
within peer groupDeals/Sales adjusts or	Deals/2011 \$ Sales	12th	Very Low	
normalises that metric relative to current sales revenue.	Deals/5 year Patent Risk	12th	Very Low	
• Deals/5 yr patent risk shows the level of activity and urgency in sourcing additional products to defend the future patent cliff challenge.				

Deal Activity League Table

Rank	Company	Rank	Company
1	Roche	7	Johnson & Johnson
2	GlaxoSmithKline	8	Merck
3	Pfizer	9	Eli Lilly
4	Sanofi	10	Bayer Healthcare
5	Novartis	11	Bristol-Myers Squibb
6	AstraZeneca	12	Abbott Laboratories

Very Low	Low	Below Average	Average	Above Average	High	Very High	
		Ab	bott	: Lab	orate	ories	
						July 2012	



Activity area	M&A		
Criteria	Mergers and acquisitions have been proven strategies in both adding revenues, creating critical mass, reducing the long term financial obligations e.g. from royalty payments, and generating profit from economies of scale. High M&A ranking indicates a successful strategic drive to survive in an increasingly consolidated market.		
Ranking M&A Activity compared	M&A Volume 13		
with peer group average	Peer Average 16.2		
	M&A Ranking 8th		
Summary	Amongst their peer group, ' Abbott Laboratories ' demonstrate ' below average ' activity in merger and acquisition growth strategy.		



Activity area	Therapy Area F	ocus	
Criteria	Companies currently operating in attractive and growing markets will direct deal activity towards these areas where current strengths can be leveraged. Those currently active in less attractive therapy areas (TA), or currently well established in high value but stagnating or genericizing therapy areas will incline deal activity towards more attractive new therapy areas where growth can add incrementally to their stable and internally supported business base.		
Top 5 Therapy	Therapy Area	% 2011 Rx and OTC sales	
Areas by revenue	Musculoskeletal	35.4%	
Aleas by levelide	Cardiology	15.0%	
	Systemic Anti-infectives	10.0%	
	CNS	6.2%	
	Endocrinology	4.6%	
Ranking	All TA In-licensing	11th	
Therapy area activity compared with peer group average	Core activity deal focus	12th	
	New TA deal focus	1st	
Summary	Amongst their peer group ' Abbott Laboratories ' show ' the lowest ' focus on their core therapeutic areas.		
	Amongst their peer group 'Abbott Laboratories' show 'the highest' diversification activity into new therapy areas.		

Activity area	Short Term Response		
Criteria	Urgency in addressing imminent revenue shortfalls, and attractiveness in courting more financially secure late stage development partners is indicated by success in licensing Phase III products. Although less risky than early stage deals, drugs at this stage are increasingly hard to find. Finding and securing Phase III drugs is a highly competitive field for Big Pharma.		
Ranking	Deal Volume 1		
Focus on late stage development	Peer Average 2.5		
	Ranking 8th		
Summary	Amongst their peer group, 'Abbott Laboratories' show 'Below Average' focus on in-licensing late stage drugs with potentially fast return on investment.		



Activity area	Long Term	Deal Investment	
Criteria	very early stage drug de entrepreneurial produc Discovery and Preclinic	Increasingly Big Pharma is looking to small start-ups as a source of very early stage drug development activity, from both a cost and entrepreneurial productivity perspective. Deal activity at the Discovery and Preclinical stage indicates a long term confidence in the business and a desire to remain at the cutting edge of science and research.	
Ranking Focus on early stage	Deal Volume	8	
development	Peer Average	40.1	
	Ranking	12th	
Summary		Amongst their peer group, 'Abbott Laboratories ' show 'the lowest ' Focus on Long Term Early Stage Investment.	



PharmaDeals Corp-METRx

Activity area	Research and Development		
Criteria	Ranking in the R&D/deals metric indicates the degree to which companies see external opportunities driving their future rather than current internal pipeline efforts. Here a high ranking is generated by a high level of deal activity relative to R&D spend, indicating external rather than internal focus.		
Ranking	R&D / All TA deal activity	\$61.21 M	
Deal activity ranking in relation to overall R&D spend	Peer Average	\$81.41 M	
	Ranking	4th	
Summary	Amongst their peer group, ' Abbott Laboratories ' show 'Above Average ' deal activity in relation to their overall R&D spend.		



Activity area

Lead Therapy Areas


Criteria

Here the peer group deal activity in the top current sales therapy area for the company is shown. This identifying deal activity threat intensity and competitors in the key revenue generating therapy area.

Ranking

Comparison of top 12 companies within top sales therapy area.

• All deal activity relates to the period starting 5 years prior to the end of the latest full month



Summary

Amongst their peer group, 'Abbott Laboratories' show average in-licensing deal activity in the Therapy Area 'Musculoskeletal'.



PharmaDeals Corp-METRx

PharmaDeals Corp-METRx

ISSN 2047-7007 (Online) DOI 10.3833/pdcmx.v2012i2.1767 Date of publication: 12 July 2012

Publisher: Fintan Walton Editor: Nigel Borshell with consultants and advisors of PharmaDeals Executive Director: Anne Vindenes Allen

Published by PharmaDeals Ltd Florey House Oxford Science Park Oxford OX4 4GP, UK

All enquires, including subscription information and permission requests: Email: enquiries@pharmaventures.com Tel +44(0)1865 332700

© 2012, PharmaDeals Ltd

All Rights Reserved. All users are expected to adhere to published Terms and Conditions for use. The contents of this publication is protected by international laws, and no part of this publication may be photocopied, transmitted or reproduced in any form without express written permission from the Publisher.

Sources: PharmaDeals v4 Agreements

Disclaimer

PharmaDeals does not warrant or assume any legal liability or responsibility for the accuracy, completeness, or usefulness of any information disclosed. The publication is in no way substitute for assistance from legal, tax, accounting, or other qualified professionals. If legal advice or other expert assistance is required, the services of a competent professional person should be sought.

PharmaDeals is a trademark of PharmaDeals Ltd.

www.pharmadeals.net

Abbott Laboratories | AstraZeneca | Bayer Healthcare Bristol-Myers Squibb | Eli Lilly | GlaxoSmithKline | Johnson & Johnson Merck | Novartis | Pfizer | Roche | Sanofi